N onalcoholic fatty liver disease (NAFLD) is a condition of increased accumulation of fat in the liver from causes other than alcohol consumption. 1 In the general population, NAFLD is associated with metabolic risk factors, such as central abdominal obesity, insulin resistance, dyslipidemia, and hypertension. 2, 3 Approximately 25 percent of NAFLD patients have nonalcoholic steatohepatitis (NASH) or liver cell injury and inflammation in addition to fat accumulation. 3 NASH can lead to fibrosis, cirrhosis, liver failure, or even hepatocellular carcinoma. 4 Globally, the prevalence of NAFLD is rising as a result of increasingly sedentary lifestyle, globalization of western diet, and improving food supplies in famine-stricken areas of the past. 3 With its increasing prevalence, NAFLD has become the predominant cause of chronic liver disease in many parts of the world. 5 In the United States, NAFLD has been reported to have a prevalence of 10 to 46 percent. [6] [7] [8] Globally, the number of patients with NAFLD has been estimated to be as high as 1 billion. 3 Diseases of the liver and the biliary tract are frequently observed in patients with inflammatory bowel disease (IBD). It has been reported that 20 percent of patients with Crohn's disease and ulcerative colitis have liver disease. 9 Abnormal liver function tests can be identified in up to 30 percent of patients with IBD. 10 Moreover, several of the drugs used for IBD treatment may induce hepatotoxicity, and therefore, routine monitoring of liver biochemical tests is recommended during treatment. 11 Traditionally, medication toxicity, primary sclerosing cholangitis, and autoimmune hepatitis were some of the most frequently identified causes. However, as the phenotype of patients with IBD continues to change from one of underweight and malnourished to overweight and even obese, there has been an increase in the number of patients identified to have NAFLD. 12 Estimates of the prevalence of NAFLD in patients with IBD have varied. In a large single-center study of 511 patients with Crohn's disease, ultrasound diagnosis of NAFLD was made in 40 percent. 13 This study excluded patients with underlying obesity or metabolic disorders. Other studies have described steatosis in up to 50% of abnormal liver biopsies in patients with IBD, and this has been related to disease severity, 14 presumed secondary to malnutrition, hypoproteinemia, and corticosteroids primarily responsible. 10 It has previously been well established that obesity is associated with an inflammatory state. 15 Patients with IBD, who are also obese, or those with more severe disease activity have a higher inflammatory burden. These individuals may be at higher risk for the development of NAFLD. It has been shown that the interaction between the innate immune system and the intestinal microbiota during obesity or autoimmunity can promote chronic liver disease progression. 16 As with other conditions of the liver and biliary system, early diagnosis and treatment is important. Patients with NASH are at increased risk for mortality from cardiovascular disease, allcause malignancy, and liver-related death. 3 When abnormal liver function tests or imaging is identified, patients will need to be evaluated for the possibility of NAFLD and risk factor reduction initiated. Currently, further study is needed to identify risk factors in patients with IBD. Our aim was to identify any associations between medications, including corticosteroids, immunomodulators, and biologics, inflammatory markers, or any frequently used laboratory parameters, such as complete blood counts, complete metabolic panel, and nutritional panels, in addition to age, disease type, duration, and metabolic risk factors.
METHODS

Design/Patient Population
A retrospective investigation was conducted from January 2015 to April 2016, on a cohort of adults diagnosed with IBD whom were enrolled in our IBD program at Houston Methodist Hospital in Houston, Texas. IBD patients with NAFLD were identified from a chart review of 421 patients seen in clinic, of which the following 3 groups were selected for our study:
1. IBD + NAFLD Group: We identified 56 patients to have NAFLD based on computed tomography (CT), ultrasound, or magnetic resonance imaging (MRI) of the liver read as having fatty infiltration by a radiologist. Of NAFLD patients, diagnosis was based on CT in 38, ultrasound in 13, and MRI in 5. 2. IBD Only Group: We identified 56 patients who had imaging studies performed that excluded NAFLD by CT in 34, ultrasound in 6, and MRI in 16. Diagnosis of IBD had previously been established in these patients based on clinical, radiological, endoscopic, and/or histological examinations. 3. NAFLD Only Group: We identified 56 age-matched controls without IBD who had been seen for a diagnosis of NAFLD at our institution during the same time frame. These patients also had NAFLD on imaging studies, CT in 8, ultrasound in 41, and MRI in 7.
The IBD registry was in compliance with the Health Insurance Portability and Accountability Act and obtained institutional review board approval for the protocol.
Data Collection
Data on demographics, laboratory data, vitamin D levels, body mass index (BMI), IBD subtype, duration of IBD, and type of medication received were collected and analyzed. Information was obtained from patient records from 2005 to 2015. The highest values on record for each patient were selected for liver function testing, BMI, erythrocyte sedimentation rate, and C-reactive protein.
The lowest values identified for each patient were selected for nutritional panels and blood counts. Medication use was documented including use of any biologic (anti-tumor necrosis factor, anti-integrin, and anti-interleukin 12/23), immunomodulator (azathioprine, mercaptopurine, and methotrexate), or corticosteroid (budesonide and prednisone). Data were collected on metabolic syndrome risk factors, including hyperlipidemia, hypertension, obesity, and diabetes based off of Adult Treatment Panel III criteria for metabolic syndrome. Hyperlipidemia was determined by patient use of a statin. Hypertension was defined as use of an antihypertensive agent. Obesity was considered as a BMI greater than or equal to 30 based off of World Health Organization (WHO) and National Institutes of Health (NIH) criteria. 17, 18 Diabetes was documented if the patient was on any medication for the treatment of diabetes or had a hemoglobin A1c value greater than or equal to 6.5%.
Statistical Analysis
Categorical variables were compared using chi-square and analysis of variance tests. Continuous variables were compared using t tests and Wilcoxon rank-sum. Univariate and multivariate analyses, odds ratios (ORs), and 95% confidence interval (CI) were calculated, and multiple logistic regression models were applied. Statistical analysis was performed using SAS version 4.0 Software.
RESULTS
Comparison Between IBD + NAFLD Group and IBD Only Group 1. Demographics: A total of 421 patients with IBD were identified in our IBD center; of whom, 56 patients were diagnosed with NAFLD. (Table 2 ). 3. Risk factors of metabolic syndrome: There was no difference in the mean BMI between the 2 groups, with 32.6 in the NAFLD only group versus 30.4 in the IBD + NAFLD patients, P ¼ 0.07. However, there were significantly more patients with obesity (BMI greater than or equal to 30.0) in the NAFLD only group compared with the IBD + NAFLD group, 59% versus 40%, respectively, P ¼ 0.03. There were also significantly more patients with hypertension in the NAFLD only group than the IBD + NAFLD group, 55% versus 33%, P ¼ 0.02, hyperlipidemia, 53% versus 17.5%, P ¼ 0.0001, and diabetes, 40% versus 16%, P ¼ 0.0001 (Table 5) .
DISCUSSION
Several important observations emerged from this study. First, the overall prevalence of NAFLD among patients with IBD was 13.3%. This is similar to a previous study in the IBD population, which found a prevalence of 8%, and comparable with the 10% to 46% prevalence rate of NAFLD seen in the U.S. population without IBD. [6] [7] [8] 19 Patients with IBD who are older, those with risk factors of metabolic syndrome, and most importantly, those with longer duration of disease irrespective of age at diagnosis, are more likely to develop NAFLD. Of the 2 previous studies evaluating risk factors of NAFLD in patients with IBD, one had only 7 patients, and another included 217 patients. 14, 19 Similar to our findings, patients with IBD who developed NAFLD were older and had increased risk factors of metabolic syndrome compared with patients with only IBD. 19 One of these studies also found that IBD patients with NAFLD had fewer metabolic risk factors compared with NAFLD patients without IBD, consistent with our results. 19 Neither of the previous studies looked into disease duration or disease activity. The finding of longer duration of disease irrespective of age at diagnosis in the IBD + NAFLD patients is an important finding that has not previously been assessed. This suggests that there may be other variables associated with IBD that over a period contribute to the development of NAFLD. This would also be consistent with our findings of fewer metabolic risk factors in IBD + NAFLD patients as compared to patients with NAFLD who do not have IBD. This could be explained by the severity of disease activity, with more severe disease predisposing to the development of NAFLD. However, disease activity as assessed by inflammatory markers (erythrocyte sedimentation rate and C-reactive protein) and anemia (hemoglobin levels) did not show any difference between the 2 groups. The second finding is the lack of significant difference in vitamin D levels between patients with and without NAFLD. Previous studies reported that vitamin D levels have been associated with IBD severity, and an association was found between vitamin D deficiency and increased risk of NASH in NAFLD patients. 20, 21 The conflict in the results could be explained by differences in cumulative effects of inflammatory activity, rather than severity as assessed by a 1-time high or low value. A patient with moderate IBD disease activity over a longer duration may have cumulatively higher levels of inflammatory activity, as opposed to one with severe disease activity for a short duration. Further studies should be conducted to determine the mean values for inflammatory markers and vitamin D levels over a longer period.
The third finding is that patients with both IBD and NAFLD had increased risk factors of metabolic syndrome compared with those with only IBD. These factors included diabetes, hypertension, obesity, and hyperlipidemia. Previous studies have found similar results with increased metabolic risk factors in IBD patients with NAFLD. 19 It is not unexpected that patients with both IBD and NAFLD have increased risk factors of metabolic syndrome, given the known association. However, in our study, patients with IBD + NAFLD had fewer risk factors of metabolic syndrome, as we found higher rates of obesity, hyperlipidemia, diabetes, and hypertension in our NAFLD only patients. This suggests that IBD itself or some component of the inflammatory state may predispose these patients to developing NAFLD without the traditional metabolic risk factors.
We did not find any significant association between the use of biological medications, corticosteroids, or immunomodulators and the development of NAFLD; however, we found a trend toward decreased use of biological medications in the IBD + NAFLD patients. There have been conflicting reports of the role of biologics, specifically tumor necrosis factor inhibitors in the development of NAFLD. 14, 19 The conflicts could be attributed to tumor necrosis factor inhibitors decreasing inflammation leading to decreased disease activity, whereas leading to mucosal healing, increased absorption of nutrients, and increased appetite, all promoting weight gain. Consequently, these factors lead to opposite effects on the overall inflammatory state by decreasing diseaserelated inflammation, but leading to weight gain, obesity-related inflammation, and metabolic syndrome. Corticosteroids, while decreasing IBD-associated inflammation, can also lead to weight gain and steatosis. 22, 23 In our study, there was no difference in corticosteroid use between the 2 groups. However, mean dose or duration of use for each patient was not assessed. Immunomodulators including azathioprine, 6-MP, and methotrexate are known to have the potential to cause liver toxicity. 24 In our study, there was no significant difference in use between groups and, therefore, does not seem to be associated with the development of NAFLD.
There are several limitations to our study. This was a relatively small group of patients who were analyzed, and patients were selected from those who were seen at our specialized IBD center. This group may represent patients with more severe disease and could have different characteristics than IBD patients with less severe disease. However, our findings were similar to previous studies that have found age and metabolic risk factors to be associated with NAFLD. Diagnosis of NAFLD was based off of imaging studies that were read by different radiologists at different times allowing for differences in interpretation. The sensitivity and specificity for ultrasound in detecting steatosis have been shown to be 85 and 94 percent, respectively, when using liver biopsy as the gold standard. 25 The sensitivities of noncontrast CT and contrast-enhanced CT for detecting hepatic steatosis have been found to be 33 and 50 percent, with specificities of 100 and 83 percent, respectively. 26 MRI has been shown to have a sensitivity of 95 and specificity of 98 percent. 27 In our study, when patients had multiple studies performed, there was typically concordance between the studies. A normal ultrasound is not sufficient to exclude NAFLD, as it is only 85 percent sensitive. Both ultrasound and CT require at least 20% to 30% fat in the liver. 25 However, all these tests have high specificity for detecting steatosis. In practice, NAFLD is often not diagnosed until steatosis is visible on imaging, consistent with our study. At our hospital, all radiologists involved in reading these imaging studies specialize in abdominal radiology, decreasing any potential for wide variability in interpretation. Because of the retrospective nature of the study, cumulative corticosteroid use could not be assessed and may need further evaluation.
In conclusion, IBD patients with longer duration of disease and increased age are at higher risk for the development of NAFLD. When compared with NAFLD only patients, IBD + NAFLD patients tended to have fewer metabolic risk factors. This suggests that there are factors associated with IBD, e.g., disease activity, which may contribute to the development of NAFLD rather than the traditional metabolic risk factors. Additional studies will be needed to further elucidate this finding. Our findings also indicate the importance of monitoring patients with IBD and encouraging a healthy lifestyle to prevent the development of NAFLD. Patients with IBD diagnosed with NAFLD will require aggressive risk factor reduction, including physical activity, weight loss, and treatment of hyperlipidemia, diabetes, and hypertension. With the increasing rates of obesity among patients with IBD, this is an issue that needs to be addressed. 
